AOD-9604 Research for Metabolic Syndrome
An overview of research and source records on AOD-9604 in the context of metabolic syndrome.
Research Summary
AOD-9604 was examined for lipid-metabolism effects in obese and beta-3-adrenoceptor knockout mice. Those animal findings do not establish an effect on metabolic syndrome or its components in people.
FDA's 2024 PCAC briefing evaluates AOD-9604 for obesity and reports a negative weight-loss result in the larger OPTIONS study; it does not establish a metabolic-syndrome indication. No clinical benefit for metabolic syndrome was verified.
References
Open a reference to inspect its source record. A citation does not establish a clinical benefit.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.